SO
TRDA icon

STRS Ohio’s Entrada Therapeutics TRDA Stock Holding History

STRS Ohio’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.6K Buy
+3,200
New +$30.7K ﹤0.01% 2108
2025
Q4 		– Sell
-3,800
Closed -$22K – 2266
2025
Q3 		$22K Sell
3,800
-41,200
-92% -$241K ﹤0.01% 2110
2025
Q2 		$302K Buy
45,000
+3,200
+8% +$25.7K ﹤0.01% 1505
2025
Q1 		$378K Buy
41,800
+9,000
+27% +$112K ﹤0.01% 1315
2024
Q4 		$567K Sell
32,800
-5,700
-15% -$103K ﹤0.01% 1112
2024
Q3 		$615K Buy
38,500
+9,900
+35% +$156K ﹤0.01% 1123
2024
Q2 		$408K Buy
28,600
+2,900
+11% +$41.2K ﹤0.01% 1341
2024
Q1 		$364K Buy
25,700
+1,600
+7% +$22.6K ﹤0.01% 1371
2023
Q4 		$363K Buy
24,100
+21,400
+793% +$317K ﹤0.01% 1407
2023
Q3 		$42K Hold
2,700
– – ﹤0.01% 1809
2023
Q2 		$40K Buy
+2,700
New +$37.2K ﹤0.01% 1832
2022
Q2 		– Sell
-2,100
Closed -$19K – 2290
2022
Q1 		$19K Hold
2,100
– – ﹤0.01% 2052
2021
Q4 		$35K Buy
+2,100
New +$50.9K ﹤0.01% 2054

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

STRS Ohio's TRDA Position: Q2 2026 in Review

STRS Ohio opened a new position in Entrada Therapeutics (TRDA) in Q2 2026: 3,200 shares worth $23.6K. The stake represents ﹤0.01% of the portfolio and ranks #2108 among its holdings. This is a return to the name: STRS Ohio previously reported a position in TRDA as recently as Q3 2025.

STRS Ohio first reported a position in TRDA in Q4 2021 and has held it in 13 quarters since. The position peaked at $615K in Q3 2024. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • STRS Ohio held 3,200 shares of Entrada Therapeutics worth $23.6K as of Q2 2026.
  • Entrada Therapeutics was a new STRS Ohio position in Q2 2026.
  • Entrada Therapeutics made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #2108 holding.
  • STRS Ohio first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 13 quarters since.
  • STRS Ohio's Entrada Therapeutics position peaked at $615K in Q3 2024.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.